MX2017004973A - Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. - Google Patents

Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.

Info

Publication number
MX2017004973A
MX2017004973A MX2017004973A MX2017004973A MX2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A MX 2017004973 A MX2017004973 A MX 2017004973A
Authority
MX
Mexico
Prior art keywords
methods
compositions
treating
subject
antisense oligonucleotide
Prior art date
Application number
MX2017004973A
Other languages
English (en)
Spanish (es)
Inventor
Giovanni Monteleone
Original Assignee
Nogra Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nogra Pharma Ltd filed Critical Nogra Pharma Ltd
Publication of MX2017004973A publication Critical patent/MX2017004973A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2017004973A 2014-10-17 2015-10-16 Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7. MX2017004973A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462065598P 2014-10-17 2014-10-17
PCT/EP2015/074066 WO2016059239A1 (en) 2014-10-17 2015-10-16 Methods and compositions for treating a subject with a smad7 antisense oligonucleotide

Publications (1)

Publication Number Publication Date
MX2017004973A true MX2017004973A (es) 2017-12-07

Family

ID=54330761

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004973A MX2017004973A (es) 2014-10-17 2015-10-16 Metodos y composiciones para tratar a un sujeto con un oligonucleotido antisentido de smad7.

Country Status (12)

Country Link
US (2) US10337004B2 (cg-RX-API-DMAC7.html)
EP (1) EP3207136A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017532961A (cg-RX-API-DMAC7.html)
KR (1) KR20170069262A (cg-RX-API-DMAC7.html)
CN (1) CN107406851A (cg-RX-API-DMAC7.html)
AU (1) AU2015332624A1 (cg-RX-API-DMAC7.html)
CA (1) CA2964667A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790867A1 (cg-RX-API-DMAC7.html)
IL (1) IL251717A0 (cg-RX-API-DMAC7.html)
MA (1) MA43331A (cg-RX-API-DMAC7.html)
MX (1) MX2017004973A (cg-RX-API-DMAC7.html)
WO (1) WO2016059239A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
EP3213070A2 (en) * 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
US11162097B2 (en) 2016-02-23 2021-11-02 Nogra Pharma Limited Methods of treating intestinal fibrosis using SMAD7 inhibition
WO2018122376A1 (en) * 2016-12-30 2018-07-05 Nogra Pharma Limited Compositions of smad7 antisense oligonucleotide and methods of treating or preventing psoriasis
CN115552005A (zh) * 2020-04-24 2022-12-30 诺格拉制药有限公司 Smad7反义寡核苷酸(aso)的组合物及其使用方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
ITRM20030149A1 (it) 2003-04-02 2004-10-03 Giuliani Spa Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
ES2627745T3 (es) 2008-11-13 2017-07-31 Nogra Pharma Limited Composiciones antisentido, y procedimientos de fabricación y uso de las mismas
NZ594281A (en) * 2009-01-26 2013-09-27 Academisch Ziekenhuis Leiden Means and methods for modulating notch3 protein expression and/or the coding region of notch3; compositions and use thereof in the treatment of cadasil
JP6018506B2 (ja) * 2010-02-08 2016-11-02 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. 対立遺伝子多様体の選択的低減
US9791442B2 (en) 2011-09-15 2017-10-17 Nogra Pharma Limited Methods of monitoring responsiveness to anti-SMAD7 therapy
CN104487574B (zh) 2012-04-18 2017-07-07 诺格尔制药有限公司 治疗糖尿病和/或促进胰岛移植后存活的方法
EP2970419B8 (en) 2013-03-15 2019-12-11 Nogra Pharma Limited Methods of treating colorectal cancer
US10006029B2 (en) 2013-03-15 2018-06-26 Nogra Pharma Limited Methods of treating colorectal cancer
RU2016147569A (ru) 2014-05-09 2018-06-13 Ногра Фарма Лимитед Способы лечения воспалительного заболевания кишечника
US20170247695A1 (en) 2014-10-17 2017-08-31 Celgene Corporation Isotopologues of smad7 antisense oligonucleotides
EP3213070A2 (en) 2014-10-17 2017-09-06 Nogra Pharma Limited Methods for dosing and monitoring smad7 antisense oligonucleotide treatment using biomarker levels
US10337004B2 (en) 2014-10-17 2019-07-02 Nogra Pharma Limited Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
MA41271A (fr) 2014-12-26 2017-10-31 Celgene Alpine Invest Company Ii Llc Méthodes d'utilisation d'oligonucléotides antisens ciblant smad7
US20180289692A1 (en) 2015-09-30 2018-10-11 Celgene Corporation Tlr modulators and methods of use
WO2017055611A2 (en) 2015-09-30 2017-04-06 Nogra Pharma Limited Methods of using smad7 antisense oligonucleotides based on biomarker expression

Also Published As

Publication number Publication date
EP3207136A1 (en) 2017-08-23
AU2015332624A1 (en) 2017-05-04
MA43331A (fr) 2017-08-23
CA2964667A1 (en) 2016-04-21
CN107406851A (zh) 2017-11-28
US20170240893A1 (en) 2017-08-24
EA201790867A1 (ru) 2017-08-31
KR20170069262A (ko) 2017-06-20
US10337004B2 (en) 2019-07-02
US20190338283A1 (en) 2019-11-07
WO2016059239A1 (en) 2016-04-21
IL251717A0 (en) 2017-06-29
JP2017532961A (ja) 2017-11-09

Similar Documents

Publication Publication Date Title
EA201790867A1 (ru) Способы и композиции для лечения субъекта антисмысловым олигонуклеотидом smad7
IL295418A (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
MX2017008184A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
PH12016502563A1 (en) Substituted nucleosides, nucleotides and analogs thereof
MX2017008183A (es) Nucleosidos sustituidos, nucleotidos y analogos de estos.
WO2016106401A3 (en) Rna agents for p21 gene modulation
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
NZ730296A (en) Modified double-stranded rna agents
PH12017500669A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
PH12016500660A1 (en) Substituted nucleosides, nucleotides and analogs thereof
CY1121037T1 (el) Αντινοηματικα πολυνουκλεοτιδια για να διεγειρεται παραλειψη εξονιου και μεθοδοι θεραπειας δυστροφιων
MX381121B (es) Supresión del gen de la huntingtina inducida por la arni
PH12015501423A1 (en) Substituted nucleosides, nucleotides and analogs thereof
EA201791820A1 (ru) Олигонуклеотидная терапия врожденного амавроза лебера
MX388737B (es) Oligonucleótidos terapéuticos.
NZ741841A (en) Antisense oligonucleotides for use in treating alzheimer’s disease
EA201791986A1 (ru) Олигонуклеотиды, соответствующие экзону 73 гена col7a1, для терапии буллезного эпидермолиза
EP3130597A4 (en) Oligonucleotide having non-natural nucleotide at 5'-terminal thereof
MX2020002110A (es) Composiciones y metodos para detectar y tratar la resistencia a la insulina.
WO2015179660A3 (en) Epigenetic engineering to study the role of aberrant dna methylation in disease
MY175723A (en) Oligonucleotides and a method for detecting and/or quantifying human metapneumovirus (hmpv)
MY194299A (en) Oligonucleotides and a method for detecting and/or quantifying human rhinovirus
PL410511A1 (pl) Sposób amplifikacji DNA w reakcji łańcuchowej polimerazy w czasie rzeczywistym za pomocą starterów metylo-specyficznych dla promotora genu DCLKI
HK1241287A1 (en) Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
MY190099A (en) Oligonucleotides and method for detecting and identifying salmonella serotypes causing non-typhoidal salmonellosis